LYT-200 is a monoclonal antibody targeting a foundational immunosuppressive protein, galectin-9, for the potential treatment of solid tumors that are difficult to treat and have poor survival rates, including pancreatic ductal adenocarcinoma, colorectal cancer and cholangiocarcinoma. PureTech today announced the initiation of a Phase 1 clinical trial of LYT-200 […]
PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment of Metastatic Solid Tumors
